Academic Journal
Precision treatment of beta-cell monogenic diabetes: a systematic review
| العنوان: | Precision treatment of beta-cell monogenic diabetes: a systematic review |
|---|---|
| المؤلفون: | Naylor, RN, Patel, KA, Kettunen, JLT, Männistö, JME, Støy, J, Beltrand, J, Polak, M, Vilsbøll, T, Greeley, SAW, Hattersley, AT, Tuomi, T |
| بيانات النشر: | Nature Research |
| سنة النشر: | 2024 |
| المجموعة: | University of Exeter: Open Research Exeter (ORE) |
| الوصف: | This is the final version. Available on open access from Nature Research via the DOI in this record ; Data availability: All data used in this systematic review are publically available in the published scientific literature. Search strategies used for each monogenic diabetes subtype are detailed in Supplemental Tables 1–5. PRISMA figures were generated in Covidence. Excel files of the included studies corresponding to each PRISMA diagram are available as supplemental data (Supplementary Data 2). ; Background: Beta-cell monogenic forms of diabetes have strong support for precision medicine. We systematically analyzed evidence for precision treatments for GCK-related hyperglycemia, HNF1A-, HNF4A- and HNF1B-diabetes, and mitochondrial diabetes (MD) due to m.3243 A > G variant, 6q24-transient neonatal diabetes mellitus (TND) and SLC19A2-diabetes. Methods: The search of PubMed, MEDLINE, and Embase for individual and group level data for glycemic outcomes using inclusion (English, original articles written after 1992) and exclusion (VUS, multiple diabetes types, absent/aggregated treatment effect measures) criteria. The risk of bias was assessed using NHLBI study-quality assessment tools. Data extracted from Covidence were summarized and presented as descriptive statistics in tables and text. Results: There are 146 studies included, with only six being experimental studies. For GCK-related hyperglycemia, the six studies (35 individuals) assessing therapy discontinuation show no HbA1c deterioration. A randomized trial (18 individuals per group) shows that sulfonylureas (SU) were more effective in HNF1A-diabetes than in type 2 diabetes. Cohort and case studies support SU’s effectiveness in lowering HbA1c. Two cross-over trials (each with 15–16 individuals) suggest glinides and GLP-1 receptor agonists might be used in place of SU. Evidence for HNF4A-diabetes is limited. Most reported patients with HNF1B-diabetes (N = 293) and MD (N = 233) are on insulin without treatment studies. Limited data support oral agents ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | https://www.ncbi.nlm.nih.gov/pubmed/39025920; Vol. 4(1), article 145; http://hdl.handle.net/10871/138493; Communications Medicine |
| DOI: | 10.1038/s43856-024-00556-1 |
| الاتاحة: | http://hdl.handle.net/10871/138493 https://doi.org/10.1038/s43856-024-00556-1 |
| Rights: | © The Author(s) 2024. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. ; https://creativecommons.org/licenses/by/4.0/ |
| رقم الانضمام: | edsbas.3FC91517 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1038/s43856-024-00556-1 |
|---|